Oxbox, Oxford, UK
Oxford Biomedica’s 84,000 sq. ft. manufacturing facility, Oxbox, was constructed during 2019. The first phase of development, totalling 45,000 sq. ft., consisted of four GMP manufacturing suites, two fill and finish suites and supporting areas such as warehouse, cold chain facilities and QC laboratories. All four GMP suites and supporting areas were approved by the MHRA during 2020 and by the fourth quarter of 2020 all four suites were in production. The first of the fill and finish suites is expected to be approved during 2021. The remaining 39,000 sq. ft. remains fallow and is available for flexible expansion in the future.
Windrush Court and Windrush Innovation Centre, Oxford, UK
Oxford Windrush Court has 32,000 sq. ft. of laboratories as well as extensive office space. Development is underway to convert some of the existing office area in Windrush Court into further laboratory space. This is to meet the growing demand for commercial development work and analytics from both current and potential future partners.
Adjoining Windrush Court is the Windrush Innovation Centre, which has a further 32,000 sq. ft. of laboratory space and is currently in the process of being refurbished. Once completed this will become the Oxford Biomedica’s dedicated innovation centre; working on both platform as well as proprietary product innovation.
Yarnton, Oxford, UK
The GMP manufacturing facility at Yarnton has both FDA and MHRA approval. It has around 6,000 sq. ft. of manufacturing space, including one clean room suite.
Harrow House and Chancery Gate, Oxford, UK
Oxford Biomedica’s Harrow House facility first received MHRA approval to manufacture in 2012. It has around 4,000 sq. ft. of manufacturing space with two GMP clean room suites. Harrow House and Chancery Gate are located directly opposite Windrush Court.
Our bespoke biomanufacturing suites include seven independent clean rooms, with potential for further expansion as required. We operate both cell factories and next generation single-use 200 L and 1000L bioreactors in dedicated production suites. These provide capacity for our internal programmes, as well as development and production for our partners, including our flagship collaboration with Novartis on its lead CAR-T therapies and AstraZeneca’s adenovirus based COVID-19 vaccine.
Our bioprocessing capabilities are supported by our process development, analytics and quality laboratories. Our GMP/GLP accredited facilities include:
• Bio-safety category three (BSL-C3) labs
• Tissue culture and cell engineering laboratories
• Process R&D labs
• QC chemistry and microbiology labs
• Analytical services and clinical analysis laboratories
• PCR, HPLC and FACS suites